Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.

Abstract

Objectives: This real-world study on small-cell lung cancer (SCLC) patients aimed to investigate treatment patterns, outcome of re-challenge with platinum doublet chemotherapy (PDCT), and associations between clinical characteristics and survival outcomes.Material and methods: This retrospective single center cohort study was based on patients diagnosed with SCLC between 2008 and 2016 at the Karolinska University Hospital, Stockholm, Sweden. Patients were divided into two subgroups; limited disease (LD), receiving concomitant chemo- and radiotherapy and extensive disease (ED), receiving palliative PDCT. The progression-free survival (PFS) was defined as the interval between the start of CT and the earliest date of documented progression. 'Refractory relapse' (Rr) and 'Sensitive relapse' (Sr) were defined as relapse occurring < or ≥180 days after start of PDCT, respectively. The results for treatment patterns were reported as numbers and percentages of patients, and descriptive analyses including medians and 95% confidence intervals (CIs). The Cox proportional hazards regression model was applied to assess the relationship between clinical characteristics and overall survival (OS).Results: The study included 544 patients; 408 with ED and 136 patients had LD. The median PFS and OS for ED patients were 5.1 and 7.0, respectively. In the ED subgroup, Sr occurred in 169 patients (41%), with a longer median OS when compared to Rr patients (10.8 vs. 3.6 months). Patients with LD had a median PFS and OS of 12 and 24 months, respectively. Some LD patients did not show a sign of relapse (22%). The majority of LD patients who relapsed had Sr (66%), with a longer median OS when compared to patients with Rr (20.9 vs. 7.8 mo).Conclusions: The survival outcomes for ED and LD SCLC patients correspond to historical data. Patients with Sr after 1st line therapy might benefit from re-challenge with PDCT in the 2nd line setting.

• Authors: Salomon Tendler, Yiqiang Zhan, Andreas Pettersson, Rolf Lewensohn, Kristina Viktorsson, Fang Fang, Luigi De Petris
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 59 Issue 4 Pg. 388-394 (Apr 2020) ISSN: 1651-226X [Electronic] England
• PMID: 31910696 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Etoposide
• Irinotecan
• Carboplatin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Irinotecan (administration & dosage)
• Lung Neoplasms (epidemiology, mortality, therapy)
• Male
• Neoplasm Recurrence, Local (epidemiology, mortality, pathology, therapy)
• Retrospective Studies
• Small Cell Lung Carcinoma (epidemiology, mortality, pathology, therapy)
• Survival Rate
• Sweden (epidemiology)
• Treatment Outcome